NFKB1 and cancer: As previously shown, the loss of VHL can activate nuclear factor‐κB (NF‐κB) in RCC cells [14, 15] and increased NF‐κB activity is associated with cancer progression in RCC patients, highlighting that the NF‐κB signaling pathway is a key regulator of immune responses and inflammation [16, 17, 18, 19].